Exact Sciences beats Wall Street expectations with $218M in sales for 3Q
Exact Sciences Corp., the Madison-based technology company that makes cancer diagnostic and detection devices, reported revenue of $218.8 million for its third quarter, beating Wall Street analysts' expectations by just over $2 million.
The maker of the Cologuard take-home colon cancer test (Nasdaq: EXAS) reported a net loss of $40.5 million, or 31 cents per share, in the quarter. Analysts had predicted net losses of 41 cents per share.
Revenue for the third quarter is up 85% relative to the year-ago…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Nick Williams Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Health Management | Profits and Losses